Abaloparatide

• Osteoporosis
• Postmenopausal bone loss
• Fracture prevention

Abaloparatide is a synthetic analog of parathyroid hormone-related protein (PTHrP) approved for the treatment of osteoporosis in postmenopausal women at high risk for fracture. This innovative medication represents an important advancement in bone health therapy, offering an alternative approach to building new bone tissue.

Mechanism of Action

Abaloparatide works by selectively activating the PTH1 receptor in a manner that preferentially stimulates bone formation over bone resorption. Unlike continuous PTH exposure which increases bone breakdown, the intermittent administration of abaloparatide produces an anabolic effect on bone tissue. The medication activates osteoblasts (bone-building cells) more effectively than osteoclasts (bone-resorbing cells), resulting in net bone gain. This selective action leads to increased bone mineral density and improved bone microarchitecture, particularly in the trabecular bone of the spine and cortical bone of the hip.

Available Formulations

Abaloparatide is available as a subcutaneous injection pen containing 80 mcg/dose. Each pen contains 30 doses, providing a one-month supply when used daily. The medication requires refrigeration until first use and can be stored at room temperature for up to 30 days after opening.

Medical Uses

The primary indication for abaloparatide is the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as those with a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. Clinical trials demonstrated significant reductions in vertebral and nonvertebral fractures compared to placebo. The medication is particularly beneficial for patients who need rapid improvements in bone density.

Dosing Guidelines

The recommended dose is 80 mcg administered subcutaneously once daily into the periumbilical region of the abdomen. Patients should rotate injection sites daily to minimize injection site reactions. The injection should be administered at approximately the same time each day. Adequate calcium and vitamin D supplementation should be maintained during treatment.

Important Safety Information

Abaloparatide carries a boxed warning regarding the potential risk of osteosarcoma based on animal studies showing dose-dependent bone tumors in rats. Due to this concern, the medication should not be used in patients at increased risk for osteosarcoma, including those with Paget's disease, unexplained elevations of alkaline phosphatase, open epiphyses, prior external beam or implant radiation therapy to the skeleton, or hereditary disorders predisposing to osteosarcoma. The cumulative lifetime use should not exceed 2 years.

Drug Interactions

Abaloparatide has minimal drug interactions due to its peptide nature. However, patients taking digoxin should be monitored as hypercalcemia can potentiate digoxin toxicity. Caution is advised when used with other medications that affect calcium levels. The medication does not significantly interact with common osteoporosis medications or calcium supplements.

Special Populations

Abaloparatide is contraindicated in pregnancy as it may cause fetal harm. The medication has not been studied in men with osteoporosis, premenopausal women, or pediatric patients. Patients with renal impairment do not require dose adjustment, though those with severe renal impairment should be monitored closely. Patients should be counseled about orthostatic hypotension, particularly during the first several doses.